

**THEORETICAL AND EXPERIMENTAL STUDIES FOR DEVELOPMENT  
AND OPTIMIZATION OF LIQUID CHROMATOGRAPHY STEPS FOR  
PURIFICATION OF A BIOTHERAPEUTIC PROTEIN**

by

**RAHUL S. BHAMBURE**

Department of Chemical Engineering

Submitted in fulfillment of the requirements of the degree of

Doctor of Philosophy

to the



**Indian Institute of Technology Delhi**

**Hauz Khas, New Delhi-110016, India**

**OCTOBER 2012**

.....Dedicated  
to my  
Parents and sister

## **CERTIFICATE**

This is to certify that the thesis entitled “ **THEORETICAL AND EXPERIMENTAL STUDIES FOR DEVELOPMENT AND OPTIMIZATION OF LIQUID CHROMATOGRAPHY STEPS FOR PURIFICATION OF A BIOTHERAPEUTIC PROTEIN**” being submitted by RAHUL S. BHAMBURE to the Indian Institute of Technology, Delhi, for the award of the degree of Doctor of Philosophy, is a record of bonafide research work carried out by him. RAHUL S. BHAMBURE has worked under my guidance and supervision and has fulfilled the requirements for the submission of the thesis.

The results contained in this thesis have not been submitted in part or in full to any other University or Institute for the award of any degree or diploma.

Prof Anurag S. Rathore  
Department of Chemical Engineering  
Indian Institute of Technology,  
Delhi-110016

## **Acknowledgement**

An endeavor cannot be completed successfully single-handedly. A few people work together for it. And it is the time for me to acknowledge those intellectuals in successful completion of my project work.

I bow down to almighty for showering his blessing on me for successful completion of the phase of my life and for all blessings he has conferred upon me.

I express my deep sense of gratitude to my guide Prof. Anurag S. Rathore, as my thesis is taking the light of the day due to his countless efforts. I am very much thankful to my guide for his cordial cooperation, enthusiasm, optimistic approach and keen interest shown in my research work. His brilliant stream of ideas, depth of knowledge has been a constant support to make me confident. His faith in me and the liberty that he gave me has helped me in bring out best in me. I really feel privileged to work under him, which made research as enhancing experience for me. I would like to remain indebted throughout my life for the encouragement and support he offered at critical times during my research life.

I am grateful to Dr. Kjell Eriksson (GE Healthcare, Sweden), Dr. Eva Heldin (GE Healthcare, Sweden), Dr. Pankaj Tahiliani (Pall Life sciences USA), Dr. Nilesh Deskmukh (Lonza Biologics, Singapore), Dr. Abijar Bhorl (Intas Biopharmaceuticals Ltd.), Dr. Pratap Bade, Prof Sudip Pattanayek and Prof Shantanu Roy for helpful discussions and for their help rendered in carrying out the experiments.

I would like to specially thank some of my best friends Sandip Hadpe (Guruji), Rakesh Mendhe (Sir), Pratap Bade, Shantanu Lale, Dinesh Labde, Kaushal Kumar, Chaitanya Sharma, Viki, Swati Shelke, Jyoti Singh, Akriti Bhalla and Jyoti Batra for scintillating cooperation during the exhaustive work period was of great importance to me. I specially acknowledge the help of Darpan Gupta, Rohit Sharma, Dushyant Garg, Muthukumar and Sandeep Hadpe for making me feel very friendly in lab hours and immense help by them whenever needed.

I would also like to gratefully acknowledge the support of Mr. Prateek Joshi, Mr. Pradeep Iyer, Mr. Yamak Mehta, Mr. Nirbhay Gandhi, Mr. Awadhesh Kumar, Mr. Kiran Akhade, Mr. Rohan Dighe, Mr. Vaibhav Deokar, Mrs. Mansi Bodani and Mrs. Devangi Patel for helpful discussions and for their help rendered in carrying out the experiments.

We acknowledge the support extended by Analytical Instrumentation Facility, IIT Delhi in analyzing the samples by SEM. I am thankful to Department of Biotechnology (DBT), Govt. of India, for sponsoring me fellowship and funds to carry out my research work. I am also thankful to Waters Corporation USA for the support in analytical characterization of GCSF and to National Institute of Biologicals, India, for performing the bioassay.

Special thanks to my parents and my relatives who have put in their efforts and prayers for me to attain success in life. I am falling short of words to express my feelings towards them. Their blessings and encouragements were beyond comparison.

.....**RAHUL**

## ABSTRACT

In today's competitive market, besides being first to the market, quality and cost-effectiveness of the product are also key drivers for process development. Protein biopharmaceutical products are typically produced along with a variety of impurities, some of which are product-related and have very similar physicochemical properties as the product itself. Methionine oxidized, reduced and fMet forms of native recombinant protein are often some of the critical quality attributes (product related impurities) associated with proteins expressed as bacterial inclusion bodies. Such oxidized and reduced impurities differ from native protein in their structural and functional aspect, causing loss of biological activity. In bacterial expression systems, such as *E. coli*, all synthesized proteins retain an amino-terminal formyl-methionine or methionine residue. This particular variant may lead to immunogenic response in patient. Lack of selective removal of these product related variants using conventional ion exchange or hydrophobic interaction chromatography is a critical bottleneck of existing manufacturing processes.

The key objective of the thesis is creation of efficient approaches for downstream processing of biotech therapeutics for removal of various product as well as host-cell related impurities. Granulocyte colony stimulating factor (GCSF) is selected as a model protein for the study. QbD based process development approach was adopted for evaluation of the various chromatography (Ion exchange and multimodal chromatography) and non chromatography (Aqueous two phase separation) based purification techniques for isolation of product variants and host-cell impurities. The experimental investigation reported in this thesis has led to several significant findings. First, a high throughput process development platform has been created to facilitate thorough but time and resource efficient examination of process chromatography steps. Second, highly efficient novel multimodal chromatography based platform has been proposed for removal of the various product as well as host cell related

impurities. And finally an aqueous two phase assisted precipitation platform has been proposed for the removal of various host related impurities. We believe that together these proposed tools can be used to create highly efficient and productive biopharmaceutical processes.

## Index

Sr. No.	Chapter details	Page No.
I	Dedication	i
II	Certificate	ii
III	Acknowledgement	iii
IV	Abstract	v
V	List of Figures	xii
VI	List of Tables	xvi

### **Chapter I: Introduction and Objective**

1.1	Purification process development for biopharmaceuticals: challenges and path forward	1
1.2	Objective of the work	3
1.3	Problem definition and scope of the research	4
1.4	Thesis Objectives	5
1.5	Organization of thesis	6

### **Chapter II: Literature survey**

2.1	Biopharmaceutical proteins or biotherapeutic proteins	8
2.2	Need of efficient and novel downstream processing platforms	9
2.3	Key impurities associated with biotherapeutic proteins	9
2.4	Process development strategies and need of empirical data modeling for efficient process optimization for downstream unit operations	12
2.5	Objective of the investigation	13

2.6	Recombinant Granulocyte Colony Stimulating Factor (GCSF)	13
2.7	Protein oxidation and need of removal of oxidized impurity of biotherapeutic proteins	15
2.8	fMet impurity of GCSF	16
2.9	Reduced impurity of GCSF	17
2.10	Path ahead for improving the downstream process platform for rHu GCSF	18
2.11	High throughput process development for biopharmaceutical products	19
2.12	Evolution of high-throughput screening methods	22
2.13	High-throughput applications in downstream process development	24
2.14	Need of improvement of exiting HTPD based chromatography platforms as a tool for QbD based early process development	28
2.15	Chromatography platform for removal of product related variants: Conventional ion exchange vs. multimodal chromatography	29
2.16	Non Chromatographic purification platform: Aqueous two phase systems (ATPS)	32
2.17	The phase diagram	34
2.18	Parameters affecting partitioning of the proteins	36
2.19	Summary	39

**Chapter III: Development of high throughput process  
development platform for process chromatography  
optimization**

3.1	Introduction	40
-----	--------------	----

3.2	Material and equipment	45
3.3	Experimental methods	47
3.4	Results and Discussion	54
3.5	Challenges involved in successful implementation of HTPD platform	62
3.6	Statistical analysis of HTPD data	66
3.7	Validation of the HTPD platform with conventional column chromatography and estimation of “design space”	68
3.8	Analysis of product quality	73
3.9	Qualitative analysis of non-specific protein adsorption	76
3.10	Summary	85

**Chapter IV: Evaluation of ion exchange chromatography for removal of various product and process related impurities**

4.1	Introduction	87
4.2	Role of ion exchange chromatography for clearance of various product and process related impurities	87
4.3	Evaluation of cation exchange chromatography	88
4.4	Evaluation of anion exchange chromatography	89
4.5	Experimental	89
4.6	Result and Discussion	91
4.7	Conclusions	98

**Chapter V: Evaluation of multimodal chromatography for removal of various product related impurities**

5.1	Introduction	100
5.2	Material and equipment	102
5.3	Experimental	103
5.4	Results and Discussion	106
5.5	DOE based optimization of operating conditions for HEA Hypercel chromatography	124
5.6	Evaluation of process analytical technology (PAT) based control strategy for multimodal chromatography step	131
5.7	Conclusion	134

**Chapter VI: Evaluation of aqueous two phase separation (ATPS) for removal of various process related impurities**

6.1	Introduction	135
6.2	Material and equipment	138
6.3	Experimental methods	139
6.4	Results	145
6.5	Discussion	168
6.6	Economic comparability analysis of aqueous two phase systems and chromatography based processes	177
6.7	Conclusions	180

## **Chapter VII: Conclusions and future scope**

7.1	Conclusion	181
7.2	Future scope	182
VII	<b>References</b>	183
VIII	<b>Appendix 1</b>	208
IX	<b>Appendix 2</b>	215
X	<b>Appendix 2</b>	218
XI	<b>Appendix 4</b>	233
XII	<b>Appendix 5</b>	262
XIII	<b>Biodata</b>	270